logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

CHAOJU EYE CARE (02219) repurchased 53,000 shares on October 20 for HK$127,000.

date
18:20 20/10/2026
avatar
GMT Eight
CHAOJ U EYE CARE (02219) announced that on October 20, 2026, it repurchased 53,000 shares for HK$127,000.
CHAOJU EYE CARE (02219) announced that on October 20, 2026, it repurchased 53,000 shares for HK$127,000.
Related Articles
China Stock
Evopoint Biosciences(688837.SH): Clinical trial application for XNW26018 tablets approved by the National Medical Products Administration
BlackRock increases its holdings in Wuxi Lead Intelligent Equipment (00470) by 413,800 shares at approximately HK$22.59 per share.
HK Stock
CICC (03908) Completes Issuance of RMB 3 Billion Perpetual Subordinated Bonds
Evopoint Biosciences(688837.SH): Clinical trial application for XNW26018 tablets approved by the National Medical Products Administration
China Stock
BlackRock increases its holdings in Wuxi Lead Intelligent Equipment (00470) by 413,800 shares at approximately HK$22.59 per share.
CICC (03908) Completes Issuance of RMB 3 Billion Perpetual Subordinated Bonds
HK Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.